Jounce Therapeutics, Inc.

Jounce Therapeutics, Inc. is at the forefront of biotechnology research, dedicated to transforming cancer treatment through innovative immunotherapies. With a commitment to enabling the immune system to effectively target tumors, Jounce Therapeutics, Inc. strives to deliver lasting benefits to patients using a biomarker-driven approach. Their work is focused on creating a world immune to cancer.

Located at 780 Memorial Drive, Cambridge, MA 02139, US, Jounce Therapeutics, Inc. has multiple programs in development and is continuously advancing early-stage assets through its robust discovery engine, which is based on its Translational Science Platform. The company’s leading program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist that has demonstrated the ability to reprogram immune-suppressive tumor-associated macrophages to an anti-tumor state in preclinical studies. The Phase 1 clinical trial, INNATE, is currently enrolling patients with advanced solid tumors to evaluate JTX-8064 as a monotherapy and in combination with JTX-4014 or pembrolizumab.

Jounce Therapeutics, Inc. is committed to pioneering advancements in cancer immunotherapy. For more detailed information and to explore potential collaborations, please visit their website. We invite the management of Jounce Therapeutics, Inc. to create a customized and exclusive company showcase and product listing on our platform, enhancing their visibility and commercial opportunities.